The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study
BACKGROUND: Although the positive cardiovascular effect of empagliflozin has been established, its influence on the formation of heart failure (HF) in patients with type 2 diabetes mellitus (T2D) after myocardial infarction (MI) remains unknown. AIM: To study the effect of empagliflozin on the forma...
Main Authors: | Alexey A. Nekrasov, Elena S. Timoschenko, Leonid G. Strongin, Tatyana A. Nekrasova, Anastasiya A. Baranova, Svetlana N. Botova, Michail V. Timoschenko, Mariya A. Yaroslavtseva |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2019-10-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://www.dia-endojournals.ru/jour/article/view/10099 |
Similar Items
-
Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia
by: Ruhua Deng, et al.
Published: (2022-10-01) -
Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq
by: Zhang P, et al.
Published: (2023-10-01) -
Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
by: Ioanna Andreadou, et al.
Published: (2017-12-01) -
Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a
by: Jana Goerg, et al.
Published: (2021-05-01) -
Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
by: Martin Benedikt, et al.
Published: (2023-07-01)